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Hip fracture patients often have comorbid conditions. We investigated whether the combination of comorbidity and
hip fracture could explain the previously observed excessmortality among hip fracture patients as compared with the
general population. Using a population-based matched study design with 38,126 Norwegian women who suffered a
hip fracture during the period 2009–2015 and the same number of women in a matched comparison cohort, we
matched participants on prefracture comorbidity, age, and education.We estimated relative survival and additive and
multiplicative comorbidity–hip fracture interactions. An additive comorbidity–hip fracture interaction of 4 or 9 addi-
tional deaths per 100 patients, depending on Charlson Comorbidity Index (CCI) score, was observed 1 year after hip
fracture. Among women with a CCI score of ≥3, 15 additional deaths per 100 patients were observed; of these, 9
deaths could be attributed to the interaction and 6 to the hip fracture per se. On the relative scale, we observed
increasing heterogeneity in survival by comorbidity over time; survival was reduced by 39% after 6 years among pa-
tients with a CCI score of≥3, while among women with no comorbidity, survival was reduced by 17% (hip fracture vs.
no hip fracture). In summary, prefracture comorbidity was associated with short-term absolute excess mortality and
long-term relative excessmortality.
cohort studies; comorbidity; hip fracture; interaction; mortality; relative survival
Abbreviations: CCI, Charlson Comorbidity Index; IC, interaction contrast; ICD-10, International Classiﬁcation of Diseases, Tenth
Revision; IQR, interquartile range; NPR, Norwegian Patient Registry.
Hip fracture is a serious and costly complication of osteopo-
rosis (1, 2). One-year mortality after hip fracture is more than
doubled, with the absolute excess mortality ranging from 8 per
100 persons to 36 per 100 persons (3–5). The increased mortal-
ity persists years after the fracture and is higher in men than in
women. Risk factors for osteoporosis include female sex, older
age, vitamin D deﬁciency, smoking, use of glucocorticoids, high
alcohol intake, lack of exercise, and low body mass index (6).
Osteoporosis and hip fracture share risk factors with several
chronic diseases, including diabetes mellitus, chronic pulmonary
disease, dementia, and cancer, which is why the prevalence of
comorbidity among patients with hip fracture is higher than that
in the general population (7). Conditions mainly responsible for
mortality after hip fracture are the same as those responsible for
mortality in the general population, rather than the speciﬁc dis-
eases related to osteoporosis (8).
Approximately 45%–60% of men and women who sustain
a hip fracture have 1 or more comorbid conditions (1, 9–11).
Comorbidity modiﬁes the clinical course of a disease, as seen
in patients with hip replacement surgery (12–14) or cancer
(15). In previous controlled studies, an association between
prefracture conditions and post–hip fracture mortality has
been reported (1, 16–18). However, whether comorbidity inter-
acts with hip fracture to produce excess mortality is not well es-
tablished (11, 19, 20). Therefore, we examined mortality after
hip fracture in a nationwide matched population-based
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cohort study of Norwegian women, comparing survival among
women with and without hip fractures according to prefracture
comorbidity using amatched cohort design.
METHODS
Setting and data sources
The source population, identiﬁed in the Norwegian National
Registry, consisted of all 935,897 women in Norway aged 55
years or older during 2008–2015. The unique personal identiﬁ-
cation number assigned to each Norwegian resident facilitated
linkage between the National Registry, the Norwegian Patient
Registry (NPR), and the Norwegian Cause of Death Registry.
The NPR is a national health registry with mandatory reporting,
covering government-funded hospitals and specialty clinics,
including data from all inpatient and outpatient hospital encoun-
ters starting in 2008 (21). In the NPR, we identiﬁed incident hip
fractures using codes from the International Classiﬁcation of
Diseases, Tenth Revision (ICD-10) (14) (see Web Table 1,
available at https://academic.oup.com/aje). The positive predic-
tive value of the hip fracture diagnosis in the NPR ranges up to
99% and is highest when used together with a surgery code
from the NOMESCO [Nordic Medico-Statistical Committee]
Classiﬁcation of Surgical Procedures (22). In this study, to cap-
ture patients who died before surgery, we deﬁned hip fracture
using ICD-10 codes alone (23). However, patients with hip
fracture diagnosed at an outpatient visit not followed by a
hospitalization were excluded if they lacked a surgical proce-
dure code (to avoid including possible readmissions—that is,
false-positive hip fractures) (Figure 1).
Data on education were obtained from the Norwegian Edu-
cation Database (24). Data on vital status were obtained from
the Norwegian Cause of Death Registry, which is 98% com-
plete (25).
Study population
We identiﬁed 47,619 women with hip fracture during
2008–2015. After exclusion of women who sustained a hip
fracture in 2008 (to ensure at least a 1-year fracture-free period
for every woman), women with a surgical procedure code for
removal of an implant, and women with an ICD-10 code for
trauma (23), the study population included 40,181 women with
incident hip fracture during 2009–2015. Among these women,
38,067 (95%) had both a diagnosis code and a procedure code,
while the remaining 2,114 women (5%) had only a diagnostic
code for hip fracture. The date of the incident hip fracture diag-
nosis was the index date.
Matching
We used a matched cohort design, with a hip fracture cohort
and a comparison cohort, as previously described (26–28).
Brieﬂy, for each woman with hip fracture, we sampled (with
replacement) 1 matched comparison woman from among those
who were alive on the index date and without a previous hip
fracture. Thematching characteristics included age (in full years)
at the index date (±3 years), highest achieved level of education
(basic (compulsory), secondary (high school/vocational),
or tertiary (college or university)) (29), and each of the 16
comorbid conditions (presence/absence) listed in the Romano
modiﬁcation of the Charlson Comorbidity Index (CCI) (30,
31). All characteristics were assessed from January 1, 2008, to
(and including) the index date. Thus, comorbid conditions re-
corded both on the index date and before the index date were
included in the matching criteria.
Follow-up of each matched pair started on the index date
and continued until death, emigration, or the end of the study
period (December 31, 2015), whichever occurred ﬁrst. Time
from the incident hip fracture to death/censoring was used as
the dependent variable. Women with a hip fracture who could
not be matched were excluded from the analysis. A woman
without a hip fracture could be used as a matched compari-
son to more than 1 woman with fracture.
Romano CCI
We used the updated Romano modiﬁcation of the CCI (31),
which is a weighted average of 16 conditions representing risk
factors relevant to our patient population, with inclusion and up-
dated weights for several of the original 19 CCI diseases, such
as dementia, diabetes with complications, and renal disease (32,
33). After matching on the individual diseases in the CCI, we
calculated CCI scores for each woman with a hip fracture and
hermatched cohort member. The validity of administrative
diagnoses included as comorbid conditions in this study varies
from 82% to 100% (34). ICD-10 codes used in the Romano
modiﬁcation of the CCI are listed inWeb Table 2.
Statistical analyses
We computed mortality risk, risk differences, additive inter-
actions, and relative survival, contrasting different combinations
of the CCI score categories (0, 1–2, or≥3) and hip fracture (yes/
no). Because of the nature of the data set, with its unequal
follow-up times and variation in mortality as a function of time
since hip fracture, we used survival analysis. We used Aalen’s
additive hazard regression model (35), which estimates the
cumulativemortality rates (hazards)B(t) separately for each com-
bination of CCI score categories and hip fracture strata. Within
each group, this is equivalent to estimating the cumulative haz-
ards using the Nelson-Aalen estimator. One important advantage
of the additive hazards model is that the contrast “hip frac-
ture (yes/no)” for a ﬁxed CCI score category will estimate the
excess mortality due to hip fracture for that category, and
because of the matched design, the matching factors will bal-
ance out in the contrast (excess risk hazards model). Mortality
risk (R) and risk differences at time t were calculated as
( ) = − ( )R t S t1 , using the formula ( ) = (− ( ))S t B texp for
survival. Relative survival (which is expressed as a ratio) was
calculated within each CCI score group j as
( ) ( ) = (−[ ( ) − ( )]) = – ≥S t S t B t B t j/ exp , 0, 1 2, 3,j j j j1 0 1 0
where the ﬁrst index refers to the presence (1) or absence
(0) of hip fracture. Multiplicative interaction was calculated as
[ ( ) ( )] [ ( ) ( )]S t S t S t S t/ / /j j1 0 10 00 . The B(t)’s were estimated
using the R package “timereg” (R Foundation for Statistical
Computing, Vienna, Austria), which allows for censoring and
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in particularmakes it possible to deal with clustered data (the lat-
ter allowing sampling of matched cohort members with replace-
ment). Note also that the matching factors will balance out
in the contrasts −R Rj j1 0 (under additive excess risk). Mortality
risk was calculated cumulatively from the index date to different
follow-up dates. This approach avoids stratiﬁcation of follow-
up time, which would have created the need for further covari-
ate adjustment.
As a measure of additive interaction between hip fracture
and comorbidity with respect to mortality, we calculated the
interaction contrast (IC) (26, 36, 37) for each CCI score cate-
gory, using the group without comorbidity as the referent. For
CCI score j, the IC was calculated as
= − − ( − ) = – ≥R R R R jIC , 1 2, 3.j j j1 0 10 00
Thus, IC1–2 measures how much more risky hip fracture is in
CCI score group 1–2 than in the group without comorbidity
( − )R R10 00 . The latter will be referred to as the risk of death
due to hip fracture per se. Thus, the interpretation of an IC1–2 of,
for example, 0.02 is that an additional 2 of every 100 patients
die because of hip fracture in CCI group 1–2, beyond what
would be expected due to hip fracture per se. We further calcu-
lated IC and relative survival by type of fracture, stratifying the
hip fractures into intracapsular, intertrochanteric, and subtro-
chanteric fractures (ICD-10 codes listed inWeb Table 1).
Including the First (Index) Hospitalization
With an ICD-10 Code for Hip Fracture in the
Study Period 2008–2015 (Unique Women)
(n = 47,619)
Excluding Women With an Index
Hospitalization in Year 2008 (n = 6,865)
Remaining Women (n = 40,754)
Excluding Women With an NCSP Code
for Removal of Implant at the Index
Hospitalization (n = 359)
Remaining Women (n = 40,395)
Excluding Women With an ICD-10 Code 
for High-Energy Trauma at the Index
Hospitalization (n = 214)
Hip Fracture Cohort Before Matching
(Incident Hip Fracture 2009–2015)
(n = 40,181)
Excluding Women With No Match on
Age, Education, and Comorbidity
(n = 2,055)
Final Cohorts
Final hip fracture cohort after 1:1 matching
     (n = 38,126)
Matched comparison cohort: nonunique
    women (n = 38,126)
Figure 1. Selection of postmenopausal women (aged ≥55 years) with hip fracture and a matched comparison cohort for a study of the role of
comorbidity in mortality after hip fracture, Norway, 2009–2015. Outpatient visits with no further hospitalization in combination with a missing code
for hip fracture surgery (NOMESCO Classiﬁcation of Surgical Procedures (NCSP)) (22) were excluded. Some women in the matched comparison
cohort were resampled: 32,405 were sampled once, 2,431 were sampled twice, 244 were sampled 3 times, and 31 were sampled 4 or more times.
ICD-10, International Classiﬁcation of Diseases, Tenth Revision; NOMESCO, Nordic Medico-Statistical Committee.
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We calculated a disease-speciﬁc IC, using the population
without hip fracture and without a given individual disease
as the reference group. For example, for myocardial infarc-
tion (MI), using the same terminology as for the CCI score,
this could be written as = − − ( −(− )R R RICMI 1MI 0MI 1 MI
)(− )R0 MI . Pointwise conﬁdence intervals for R, risk differ-
ences, and additive interactions were obtained using the delta
method (38).
RESULTS
The hip fracture and comparison cohorts consisted of 38,126
successfully matched pairs; therefore, the cohorts had the same
distributions of age, comorbidity, and education at baseline
(Table 1). A total of 2,055 (5%) women with hip fracture who
could not be matched were excluded from the analysis. The
unmatched women were slightly older, with a median age
of 85 years (interquartile range (IQR), 78–90) as compared
with 84 years (IQR, 77–89) among thematchedwomen, and had
a 96% prevalence of a CCI score of ≥3 as compared with 36%
of those matched.
Median age at the index date and IQRs were similar by CCI
score group in the 2 cohorts; median ages were 83 years (IQR,
75–89), 84 years (IQR, 77–89), and 85 years (IQR, 80–90) for
groups with CCI scores of 0, 1–2, and ≥3, respectively. Median
survival was 4.1 years and 5.8 years for the cohorts with and
without hip fracture, respectively.
Table 1 shows baseline demographic and clinical character-
istics of the hip fracture cohort and the comparison cohort.
Dementia was the most prevalent disease (18%), followed by
chronic pulmonary disease, myocardial infarction, and cere-
brovascular disease (each about 13%). Among the less preva-
lent diseases were moderate or severe liver disease (0.1%),
hemiplegia (0.3%), and mild liver disease (0.3%).
The mortality risk increased with increasing CCI score for
both women with hip fracture and women without hip fracture
(Table 2). Within each CCI score category, using the cohort
without hip fracture as the reference group, the risk difference
increasedwith longer follow-up time for CCI scores of 0 and 1–2,
while for CCI scores of ≥3, the risk difference increased up to
365 days following the index date and then decreased. There was
a positive additive interaction for CCI score categories of 1–2
and ≥3, ﬁrst increasing and then decreasing over time. After a
maximum of 6 years of follow-up, no additive interaction was
observed. Relative survival decreased for increasing CCI score
and for increasing follow-up time (Table 2). After 6 years of
follow-up, relative survival was 0.83, 0.74, and 0.61 for CCI
scores of 0, 1–2 and ≥3, respectively, with multiplicative in-
teractions of 0.89 (CCI score 1–2) and 0.73 (CCI score≥3).
The following diseases showed a positive additive interaction
with hip fracture during the ﬁrst year of follow-up (in declining
order of importance): metastatic solid tumor (IC = 0.21);
congestive heart failure (IC = 0.08); moderate/severe renal dis-
ease (IC = 0.07); dementia (IC = 0.06); any tumor, leukemia,
or lymphoma (IC = 0.06); myocardial infarction (IC = 0.05);
chronic pulmonary disease (IC = 0.04); and cerebrovascular
disease and peripheral vascular disease (IC = 0.03). There was
a negative additive interaction for connective tissue disease
(IC = −0.03) (Figure 2). After 6 years of follow-up, there
Table 1. Baseline Characteristics of a Cohort of 38,126
Postmenopausal WomenWith Hip Fracture and a Nonunique
Matched Comparison Cohort, Norway, 2009–2015
Baseline Characteristic No. ofPersons %
Age at index date, yearsa 84 (77–89)
Index year
2009 5,863 15.4
2010 5,630 14.8
2011 5,568 14.6
2012 5,512 14.5
2013 5,364 14.1
2014 5,211 13.7
2015 4,978 13.1
Individual disease in the CCIb
Myocardial infarction 4,809 12.6
Congestive heart failure 4,356 11.4
Peripheral vascular disease 1,761 4.6
Cerebrovascular disease 4,764 12.5
Dementia 7,026 18.4
Chronic pulmonary disease 4,984 13.1
Connective tissue disease 1,693 4.4
Ulcer disease 876 2.3
Mild liver disease 104 0.3
Diabetes 3,456 9.1
Diabetes with end organ damage 1,322 3.5
Hemiplegia 97 0.3
Moderate or severe renal disease 1,776 4.7
Any tumor, leukemia, lymphoma 4,661 12.2
Moderate or severe liver disease 34 0.1
Metastatic solid tumor 804 2.1
CCIb score at baseline
0 14,697 38.5
1 3,997 10.5
2 5,480 14.4
3 6,269 16.4
4 2,815 7.4
5 2,157 5.7
6 1,459 3.8
7 571 1.5
8 387 1.0
9 189 0.5
10 75 0.2
11 25 0.1
12 5 0.0
Highest achieved educational level
Basic education (compulsory) 18,820 49.4
Secondary education (high school/vocational
education)
15,477 40.6
Tertiary education (college/university) 3,545 9.3
Unknown 284 0.7
Abbreviation: CCI, Charlson Comorbidity Index.
a Value is expressed asmedian (interquartile range).
b Romanomodiﬁcation of the CCI.
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Table 2. Mortality Risk, Risk Difference, Additive andMultiplicativea Comorbidity–Hip Fracture Interaction, and Relative Survival (Measured Cumulatively From the Index Date) in a Cohort of
38,126 Postmenopausal WomenWith Hip Fracture and a NonuniqueMatched Comparison Cohort, Norway, 2009–2015b
CCIc Score
Matched Comparison Cohort
(Cohort Without Hip Fracture) Hip Fracture Cohort
RDd 95%CI ICe 95%CI RelativeSurvivald 95%CINo. of
Deaths
No. of
Person-Years Risk 95%CI
No. of
Deaths
No. of
Person-Years Risk 95%CI
≤30 Days of Follow-up
0 49 1,200 0.003 0.002, 0.004 408 1,184 0.03 0.024, 0.030 0.02 0.021, 0.027 0 Referent 0.98 0.97, 0.98
1–2 51 772 0.01 0.004, 0.007 515 749 0.05 0.049, 0.058 0.05 0.044, 0.054 0.03 0.018, 0.032 0.95 0.95, 0.96
≥3 262 1,129 0.02 0.016, 0.021 1,499 1,068 0.11 0.102, 0.112 0.09 0.083, 0.094 0.06 0.059, 0.070 0.91 0.90, 0.92
≤365 Days of Follow-up
0 721 13,571 0.05 0.048, 0.056 1,565 12,898 0.11 0.105, 0.116 0.06 0.052, 0.064 0 Referent 0.94 0.93, 0.94
1–2 693 8,498 0.08 0.072, 0.084 1,610 7,782 0.18 0.169, 0.185 0.10 0.090, 0.109 0.04 0.027, 0.055 0.89 0.88, 0.90
≥3 2,419 11,696 0.19 0.179, 0.194 4,522 9,841 0.34 0.330, 0.347 0.15 0.141, 0.162 0.09 0.084, 0.103 0.81 0.80, 0.83
≤3 Years of Follow-up
0 2,077 33,556 0.17 0.165, 0.181 3,155 31,379 0.25 0.244, 0.261 0.08 0.069, 0.091 0 Referent 0.90 0.89, 0.92
1–2 1,768 19,960 0.24 0.228, 0.248 2,893 17,646 0.37 0.356, 0.379 0.13 0.115, 0.144 0.05 0.026, 0.074 0.83 0.81, 0.85
≥3 5,189 24,790 0.47 0.458, 0.480 7,057 20,261 0.60 0.587, 0.606 0.13 0.113, 0.142 0.05 0.033, 0.061 0.76 0.74, 0.79
≤6 Years of Follow-up
0 3,192 47,316 0.36 0.342, 0.368 4,469 43,260 0.47 0.455, 0.480 0.11 0.096, 0.129 0 Referent 0.83 0.80, 0.85
1–2 2,578 26,534 0.47 0.456, 0.490 3,728 22,807 0.61 0.594, 0.628 0.14 0.115, 0.161 0.03 −0.019, 0.070 0.74 0.70, 0.78
≥3 6,505 30,256 0.75 0.732, 0.760 8,243 24,137 0.85 0.836, 0.858 0.10 0.083, 0.119 −0.01 −0.031, 0.008 0.61 0.55, 0.66
Abbreviations: CCI, Charlson Comorbidity Index; CI, conﬁdence interval; IC, interaction contrast; RD, risk difference.
a Multiplicative interaction (relative survival): ≤30 days of follow-up—CCI score 1–2: 0.97 (95% CI: 0.97, 0.98); CCI score ≥3: 0.93 (95% CI: 0.93, 0.94); ≤365 days of follow-up—CCI score
1–2: 0.95 (95% CI: 0.93, 0.97); CCI score ≥3: 0.87 (95% CI: 0.85, 0.88); ≤3 years of follow-up—CCI score 1–2: 0.92 (95% CI: 0.89, 0.95); CCI score ≥3: 0.84 (95% CI: 0.81, 0.88); ≤6 years of
follow-up—CCI score 1–2: 0.89 (95%CI: 0.83, 0.97); CCI score≥3: 0.73 (95%CI: 0.66, 0.82).
b All risk measures are dimensionless and have no units.
c Romanomodiﬁcation of the CCI.
d Calculated within each CCI score category, using the cohort without hip fracture as the reference group.
e Additive comorbidity–hip fracture interaction, calculated using the cohort with CCI score equal to zero as the reference group.
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was little evidence of any interaction except for dementia
(IC = −0.06) andmetastatic solid tumor (IC = 0.12) (Figure 3).
Stratifying the analysis by type of hip fracturemainly resulted
in slightly higher ICs at 1 year of follow-up for intracapsular
and subtrochanteric fractures as compared with intertrochan-
teric fractures (Web Tables 3–5).
DISCUSSION
Main ﬁndings
In this large population-based cohort study of postmenopausal
women, the absolute excess risk inmortality amongwomenwho
sustained a hip fracture and had comorbidity was higher than
could be explained by the hip fracture per se. The absolute excess
risk was observed during the ﬁrst year of follow-up; thereafter,
no excess risk due to the additive interactionwas found. The esti-
mated additive interaction increased with number of comorbid
conditions (CCI score), ranging between 3 and 9 additional
deaths per 100 patients during the ﬁrst year after a hip fracture.
Nevertheless, the mortality risk of hip fracture per se remained
increased after 6 years of follow-up. Despite little evidence of
any additive interaction between hip fracture and comorbidity
after 6 years, we observed an interaction on the multiplicative
scale, in the form of decreasing relative survival (hip fracture
vs. no hip fracture) as a function of time.
Comparisonwith other studies
Several clinical studies have found an association between
prefracture comorbidity and hip fracture survival (1, 39–42).
Prefracture conditions such as cardiac disease, dementia, renal
disease, and chronic obstructive pulmonary disease have been
identiﬁed as predictors of 30-day (41) and 1-year (1) mortality.
Previous cohort studies of the association of hip fracture and
comorbidity with mortality have matched hip fracture patients
and general-population cohort members on age and sex but
not on prefracture comorbidity or education (11, 18, 19, 42).
An excess risk of myocardial infarction up to 1 year after a hip
fracture and for stroke up to 10 years postfracture was found in
a recent population-based Danish study (42), where the attribut-
able fraction of any of the outcomes within 30 days due to the
interaction between hip fracture and comorbidity was estimated
to be 76%. Several cohort studies have indicated an association
between prefracture comorbidity and post–hip-fracture mortal-
ity (16, 18, 43), but these studies have been small and the inves-
tigators have not presented anymeasures of interaction.
In contrast to our study, Vestergaard et al. (11) found little
association between prefracture comorbidity and excess hip
Disease Category
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Connective tissue disease
Ulcer disease
Mild liver disease
Diabetes
Diabetes with end organ damage
Hemiplegia
Moderate or severe renal disease
Any tumor, leukemia, or lymphoma
Moderate or severe liver disease
Metastatic solid tumor
0.05 (0.04, 0.07)
0.08 (0.06, 0.10)
0.03 (0.00, 0.05)
0.03 (0.01, 0.04)
0.06 (0.04, 0.07)
0.04 (0.02, 0.06)
−0.03 (−0.06, −0.01)
0.02 (−0.01, 0.06)
−0.04 (−0.13, 0.05)
−0.02 (−0.04, 0.00)
−0.03 (−0.06, 0.00)
−0.10 (−0.19, 0.00)
0.07 (0.04, 0.10)
0.06 (0.04, 0.08)
0.07 (−0.12, 0.25)
0.21 (0.17, 0.26)
IC (95% CI)
−0.2 −0.1 0.10 0.2 0.3
Interaction Contrast
Figure 2. Interaction contrast (IC; additive comorbidity–hip fracture interaction) between hip fracture and individual diseases included in the
Romano modiﬁcation of the Charlson Comorbidity Index at a maximum of 1 year of follow-up, Norway, 2009–2015. Data were available for 38,126
Norwegian womenwith hip fracture and amatched comparison cohort. Bars, 95% conﬁdence intervals (CIs).
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fracture mortality in a large population-based Danish study. The
authors attributed 70%of deaths to complications that arose dur-
ing the ﬁrst 30 days postfracture (the hip fracture per se) and at-
tributed long-term excess mortality to several factors, including
income. At the same time, causes contributing to excess mor-
tality included infections, psychiatric disease, pulmonary dis-
ease, dementia, and neurological diseases—conditions that
may have been present before the hip fracture. A similar con-
clusion was drawn in a recent Australian study by Lystad et al.
(44), where 72% of the 1-year post–hip-fracture mortality was
found to be attributed to the hip fracture per se. There could be
several reasons for this higher proportion being explained by
the hip fracture per se. In the Australian study, hip fracture pa-
tients were 3 times more likely to die within 12 months than
people without fracture, as compared with a doubling of the
risk in our study. Both Vestergaard et al. (11) and Lystad et al.
(44) included men in their studies, and the matches (controls)
had to be free of hip and femur fracture during the study period.
In our study, we did not impose this requirement; we required
only that the matches be free of fracture from the index date
onward and back to 2008. Further, we matched on comorbidity
in the baseline period, including the index hospitalization and
going back to 2008, while both Vestergaard et al. and Lystad
et al. used a 12-month look-back period.
We found that for many of the comorbid conditions studied,
the risk of 1-year mortality was increased beyond that due to the
hip fracture per se. Exceptions were hemiplegia and connective
tissue diseases, where the additive interaction was negative.
Many patients with connective tissue disease are treated with
glucocorticoids, whichmay lead to bone degradation. This often
prompts simultaneous treatment with bone-protecting agents,
usually bisphosphonates. Intravenous treatment with bis-
phosphonate may have a preventive effect against mortal-
ity, as well as against hip fracture (45). One may speculate
as to whether this accounts for some of the negative addi-
tive interaction between connective tissue disease and mortal-
ity after a hip fracture. The largest negative IC was estimated
for patients with hemiplegia 1 year postfracture. In contrast,
increased mortality in patients suffering from poststroke hemi-
plegia has been described previously and was explained by
more overall comorbidity (46).
Strengths andweaknesses
This was a nationwide population-based cohort study de-
signed to examine the combined role of hip fracture and comor-
bidity in mortality among postmenopausal women. Because
hip fracture invariably leads to hospitalization and because all
Disease Category
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
Chronic pulmonary disease
Connective tissue disease
Ulcer disease
Mild liver disease
Diabetes
Diabetes with end organ damage
Hemiplegia
Moderate or severe renal disease
Any tumor, leukemia, or lymphoma
Moderate or severe liver disease
Metastatic solid tumor
0.00 (−0.04, 0.03)
−0.03 (−0.06, 0.00)
0.03 (−0.04, 0.10)
0.02 (−0.02, 0.05)
−0.06 (−0.09, −0.04)
0.05 (0.01, 0.08)
−0.01 (−0.06, 0.05)
  0.00 (−0.10, 0.10)
−0.02 (−0.28, 0.25)
−0.04 (−0.08, 0.00)
−0.04 (−0.11, 0.02)
−0.19 (−0.40, 0.02)
−0.01 (−0.07, 0.04)
  0.05 (0.01, 0.09)
−0.10 (−0.42, 0.23)
  0.12 (0.05, 0.19)
IC (95% CI)
−0.2 −0.1 0.10 0.2
Interaction Contrast
Figure 3. Interaction contrast (IC; additive comorbidity–hip fracture interaction) between hip fracture and individual diseases included in the
Romanomodiﬁcation of the Charlson Comorbidity Index at a maximum of 6 years of follow-up, Norway, 2009–2015. Data were available for 38,126
Norwegian womenwith hip fracture and amatched comparison cohort. Bars, 95% conﬁdence intervals (CIs).
Am J Epidemiol. 2019;188(2):398–407
404 Lunde et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/article-abstract/188/2/398/5166372 by R
oyal Library C
openhagen U
niversity user on 20 M
arch 2019
hospitalizations in Norway are registered in the NPR, virtually
all hip fractures that occurred in Norway during the study
period were identiﬁed, also including the 5% identiﬁed by ICD-
10 codes alone. Missing a code for surgery did not change study
results substantially, suggesting that risk of selection bias in
our study was minimal. Mortality data in the Norwegian Cause
of Death Registry have a completeness of 98% (47).
Although we matched women with hip fracture to women
without hip fracture by age, education, and comorbidity, the re-
sults may be partially explained by potential residual confound-
ing by unmeasured characteristics inherent in a registry-based
study, such as smoking, body mass index, use of drugs that may
induce osteoporosis, or disease severity (48).
Women with hip fracture for whom we did not ﬁnd a match
were excluded (5%). These women had more comorbidity and
shorter survival than the hip fracture cohort, which may poten-
tially have biased the ICs towards zero. The use of duplicates
(repeated sampling) in the matched cohort could also potentially
have biased our estimated standard deviations.We therefore con-
ducted a bootstrap-type sensitivity study, which showed that the
use of duplicate matches had little effect on the estimated stan-
dard deviations (less than 5%bias).
Comorbidity was measured for a minimum of 1 year and a
maximum of 6 years before the index date and included acute
ﬁrst-time diagnoses made during the index hospitalization.
This approach implicitly assumes that acute events may result
from an ongoing underlying clinical condition. However, one
might argue that the acute condition represents a complication
or trauma arising from the hip fracture, rather than part of a
preexisting condition, and therefore should not be included as
a matching variable (49). Further, use of the Romano modiﬁ-
cation of the CCI (31) required translation of codes from the
International Classiﬁcation of Diseases, Ninth Revision, to
the ICD-10 (34, 50, 51). This modiﬁed index may have omit-
ted some acute diseases, such as infections, that could interact
with hip fracture to cause excess mortality.
An additional concern is that relatively less severe diseases,
such as diabetes, which do not typically lead to hospital encoun-
ters, are incompletely captured by the NPR (21). As a conse-
quence, counting the number of comorbid conditions at the
index hospitalization has some potential for overmatching. To
evaluate the potential bias, we doubled the disease frequency of
each of the 16 disease categories in the source population (eligible
matches) before matching the hip fracture cohort. The estimated
ICs increased approximately 50% at 1-year follow-up to 0.06 and
0.14 for CCI scores of 1–2 and≥3, respectively, and after 6 years
of follow-up the estimated ICswere 0.08 and 0.09, respectively.
Many women had a hospital diagnosis of dementia at the
time of the index hospitalization. Nearly 50% of these diagnoses
were registered for the ﬁrst time, which suggests that dementia
may not be well captured by the NPR or that many patients are
wrongly diagnosed with dementia in an acute-care setting, such
as hospitalization due to a hip fracture. If the latter is true, we
could expect to see the absolute excess risk change from posi-
tive to negative over time, as we actually observed. However,
repeating the analyses after excluding all diagnosis made on the
index date from the matching did not increase the IC for demen-
tia; rather, the IC decreased slightly, from−0.06 to−0.07.
There was a slight gradual rightward shift in the age distri-
bution with increasing CCI score. This could potentially have
biased some of the ICs. We therefore performed a stratiﬁed
analysis, calculating the IC within 1-year age groups followed
by a pro-rata weighting of the ICs. This changed the ICs for
some of the CCI scores by up to 0.02 units in either direction.
Given the increasing number of patients with comorbidity
due to advanced age and the high mortality among hip fracture
patients, optimizing the preoperative and postoperative care of
patients with chronic heart, renal, or pulmonary disease, as well
as focusing on complications (e.g., infections) known to be
related to these diseases, could potentially reducemortality.
Conclusion
This study conﬁrms that mortality among women with
comorbidity is excessively high after a hip fracture.
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